Intra-Cellular Therapies

ITCI

1 Followers
$131.87 +0.00% $0.00
Follow
N/A
Upcoming Earnings
 
Market Cap.
 
P/E
Overview Metrics Financials
Loading...

ITCI Fair Price

$78.49
Overvalued by 02.0%
To display the fair price of a share, you need to be a member of Bulios Black.

My Notes

Začít psát

Profile

Intra-Cellular Therapies is an American biotechnology company focused on developing new therapeutic options for the treatment of neuropsychiatric disorders, including schizophrenia, bipolar disorder, and other mental health conditions. The company employs advanced technologies focused on cellular signaling and neurobiology to create innovative drugs that target specific molecular pathways in the brain. Intra-Cellular Therapies is known for its research in neurology and psychiatry, aiming to improve the lives of patients suffering from these challenging diseases.

Feed

3M
Read More

💡 Johnson & Johnson: $14.6 billion acquisition strengthens the pharmaceutical giant's position in the neurological drugs market 💊

Johnson & Johnson $JNJ, one of the biggest players in the healthcare industry, has once again shown that growth through strategic acquisitions is their forte.

The company announced last week the purchase of biopharmaceutical firm Intra-Cellular...
Read more
11
Share
Zobrazit další komentáře

It's not a bad business, but I'd rather buy something riskier. Plus this stock isn't growing as mentioned and I don't see why it should start growing.
Like 0 1
Don't have an account? Join us

Log in to Bulios

Continue with Google
Continue with Apple
Continue with Facebook
Or use email and password
Reset password
Already a member? Log in

Create Bulios profile

Continue with
Or use email and password
You can use lowercase letters, numbers, and underscores

Why Bulios?

One of the fastest growing investor communities in Europe

Comprehensive data on thousands of stocks from around the world

Current information from global markets and individual companies

Education and exchange of investment experience among investors

Fair prices, portfolio tracker, stock screener and other tools
Menu StockBot
Tracker
Upgrade